Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 498

1.
3.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200
4.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.

Hudis CA, Vogel CL, Gralow JR, Williams D; Procrit Study Group..

Clin Breast Cancer. 2005 Jun;6(2):132-42.

PMID:
16001991
5.

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.

Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M; Epoetin Alfa Study Group..

Hematol Oncol. 2003 Dec;21(4):169-80.

PMID:
14735555
9.

Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.

Cartenì G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P; OBI/EPO-ITA-01/1 study group..

Support Care Cancer. 2007 Sep;15(9):1057-66. Epub 2007 Apr 13.

PMID:
17431689
11.

Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.

Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC; POWER Study Group..

Clin Nephrol. 2004 Jun;61(6):392-405.

PMID:
15224803
12.

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.

Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group..

Clin Nephrol. 2005 Aug;64(2):113-23.

PMID:
16114787
13.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Cancer. 2002 Aug 15;95(4):888-95.

14.

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

Chang J, Couture F, Young S, McWatters KL, Lau CY.

J Clin Oncol. 2005 Apr 20;23(12):2597-605. Epub 2004 Sep 27. Erratum in: J Clin Oncol. 2005 Aug 1;23(22):5276.

PMID:
15452188
15.
16.

Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.

Granetto C, Ricci S, Martoni A, Pezzella G, Testore F, Mattioli R, Lampignano M, Tacconi F, Porrozzi S, Gasparini G, Mantovani G; EPO-ITA3 Study Group..

Oncol Rep. 2003 Sep-Oct;10(5):1289-96.

PMID:
12883695
17.

Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.

Ots PM, Pérez AR, Carrizosa CL, Ocaña CV, de Dios Sáez Garrido J, Delgado Pérez JM.

Clin Transl Oncol. 2005 Dec;7(11):486-92.

PMID:
16373059
18.

Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.

Oncologist. 2004;9(1):90-6. Erratum in: Oncologist. 2004;9(2):240.

19.

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF.

J Clin Oncol. 2005 Apr 20;23(12):2606-17. Epub 2004 Sep 27.

PMID:
15452187
20.

Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.

Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Vlahos L.

Anticancer Res. 2005 Sep-Oct;25(5):3495-500.

Supplemental Content

Support Center